List of Jevtana Kit drug patents
Jevtana Kit is owned by Sanofi Aventis Us.
Jevtana Kit contains Cabazitaxel.
Jevtana Kit has a total of 6 drug patents out of which 0 drug patents have expired.
Jevtana Kit was authorised for market use on 17 June, 2010.
Jevtana Kit is available in solution;intravenous dosage forms.
Jevtana Kit can be used as increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist, increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist, increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist.
The generics of Jevtana Kit are possible to be released after 27 April, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7241907 | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Dec, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7241907
(Pediatric) | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Jun, 2026
(3 years from now) | |
| US10583110 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(7 years from now) | |
| US10716777 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(7 years from now) | |
| US8927592 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(7 years from now) | |
|
US8927592
(Pediatric) | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Apr, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Dec 18, 2023 |
Drugs and Companies using CABAZITAXEL ingredient
Market Authorisation Date: 17 June, 2010
Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist; Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist
Dosage: SOLUTION;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic